- It has been nearly one year since I took a good look at Lantheus Holdings, but PYLARIFY's approval has forced me to reassess the ticker and my investment strategy.
- PYLARIFY has the potential to be a game-changer in prostate cancer diagnosis and improve patient outcomes. The company has been hard at work preparing for launch in the USA.
- I discuss why PYLARIFY's approval has revitalized my bullish outlook. In addition, I reveal my strategy for accumulating a larger position in LNTH.
For further details see:
Lantheus Holdings: PYLARIFY Approval Revitalizes My Bullish Outlook